Skip to content

Study · Animal study (in vivo) · rat · 2016

4 results

Hydrogel Drug Delivery System Using Self-Cleaving Covalent Linkers for Once-a-Week Administration of Exenatide.

Schneider EL, Henise J, Reid R, Ashley GW, Santi DV

Bioconjugate chemistry22 Mar 2016Cited by 27 (Europe PMC)

PMID26930186 (opens in a new tab)DOI10.1021/acs.bioconjchem.5b00690 (opens in a new tab)PepBankPUB-26930186
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Pharmacokinetics

    In rats, hydrogel microspheres released exenatide with a half-life of about 7 days, extending half-life over 300-fold.

    In plain wordsIn rats, hydrogel microspheres extended exenatide half-life over 300-fold.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseReleased exenatide half-life
    Study

    ratn: not reported in source

    Hydrogel-exenatide microspheres
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · subcutaneousAs given in this study (rat).

    Measurements

    Half-life
    ≈ 7 days
    released exenatide
    Half-life extension
    > 300 fold
    rat

    Source sentences

    Summary
    Pharmacokinetic analysis showed a t1/2,β of released exenatide of about 7 days which represents over a 300-fold half-life extension in the rat and exceeds the half-life of any currently approved long-acting GLP-1 agonist.
    2 context sentences
    Summary · context
    The peptide was covalently attached to Tetra-PEG hydrogel microspheres by a cleavable β-eliminative linker; upon s.c. injection, the exenatide is slowly released at a rate dictated by the linker.
    Summary · context
    The exenatide-laden microspheres were injected subcutaneously into the rat, and serum exenatide measured over a one-month period.
  2. 02AnimalAnimal study (in vivo)Pharmacokinetics

    In rats, exenatide release from hydrogel conjugates was 3-fold faster in vivo than in vitro.

    In plain wordsIn rats, exenatide release was faster than in lab tests.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseIn vivo versus in vitro release rate
    Study

    ratn: not reported in source

    Hydrogel-exenatide microspheres
    Comparator
    In vitro release
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · subcutaneousAs given in this study (rat).

    Measurements

    Release-rate ratio
    3 fold
    in vivo versus in vitro

    Source sentences

    Summary
    Hydrogel-exenatide conjugates gave an excellent Level A in vitro-in vivo correlation of release rates of the peptide from the gel, and indicated that exenatide release was 3-fold faster in vivo than in vitro.
    2 context sentences
    Summary · context
    The peptide was covalently attached to Tetra-PEG hydrogel microspheres by a cleavable β-eliminative linker; upon s.c. injection, the exenatide is slowly released at a rate dictated by the linker.
    Summary · context
    The exenatide-laden microspheres were injected subcutaneously into the rat, and serum exenatide measured over a one-month period.

Studies that did not test the peptide alone2

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 03AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Pharmacokinetics

    Hydrogel-exenatide conjugates showed a Level A correlation between in vitro and in vivo peptide release rates.

    In plain wordsIn lab and animal tests, hydrogel-exenatide release rates showed a Level A correlation.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableRelease-rate correlation
    Study

    ratn: not reported in source

    Hydrogel-exenatide microspheres
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    Hydrogel-exenatide conjugates gave an excellent Level A in vitro-in vivo correlation of release rates of the peptide from the gel, and indicated that exenatide release was 3-fold faster in vivo than in vitro.
    2 context sentences
    Summary · context
    The peptide was covalently attached to Tetra-PEG hydrogel microspheres by a cleavable β-eliminative linker; upon s.c. injection, the exenatide is slowly released at a rate dictated by the linker.
    Summary · context
    The exenatide-laden microspheres were injected subcutaneously into the rat, and serum exenatide measured over a one-month period.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  2. 04Computer modelNot a test of Exenatide (exendin-4) aloneIn silicoOther

    Pharmacokinetic simulations suggested that hydrogel-exenatide microspheres could support weekly or biweekly subcutaneous dosing in humans.

    In plain wordsComputer simulations suggested weekly or biweekly human dosing for hydrogel-exenatide microspheres.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableSimulated dosing interval
    Study

    humann: not reported in source

    Pharmacokinetic simulations
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    Pharmacokinetic simulations indicate that the hydrogel-exenatide microspheres should support weekly or biweekly subcutaneous dosing in humans.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.